Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2025 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

viatris inc. - VTRS

VTRS

Close Chg Chg %
8.60 0.49 5.70%

Pre-Market

9.09

+0.49 (5.70%)

Volume: 30.07M

Last Updated:

May 8, 2025, 4:00 PM EDT

Trade Now

Company Overview: viatris inc. - VTRS

VTRS Key Data

Open

$9.00

 Day Range

8.91 - 9.58

52 Week Range

6.85 - 13.55

 Market Cap

$10.20B

Shares Outstanding

1.19B

 Public Float

1.16B

Beta

0.89

 Rev. Per Employee

N/A

P/E Ratio

N/A

 EPS

-$0.53

Yield

566.04%

 Dividend

$0.12

EX-DIVIDEND DATE

May 23, 2025

 SHORT INTEREST

N/A

AVERAGE VOLUME

14.25M

  

VTRS Performance

1 Week
 
 -0.58%
 
1 Month
 
 14.06%
 
3 Months
 
 -19.85%
 
1 Year
 
 -22.94%
 
5 Years
 
 N/A
 

VTRS Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 11
Full Ratings ➔

About viatris inc. - VTRS

Viatris, Inc. is a global healthcare company, which engages in the provision of healthcare and pharmaceutical products. It provides medicines and treatments in various therapeutic areas such as cardiovascular, oncology, dermatology, eye care, gastroenterology, immunology, and women's healthcare. The firm operates through the following segments: Developed Markets, Greater China, JANZ, and Emerging Markets. The Developed Markets segment consists of operations primarily in North America and Europe. The Greater China segment includes operations in mainland China, Taiwan, and Hong Kong. The JANZ segment covers operations in Japan, Australia, and New Zealand. The Emerging Markets segment encompasses operations in developing markets and emerging economies including in Asia, the Middle East, South and Central America, Africa, and Eastern Europe. The company was founded on February 14, 2019 and is headquartered in Canonsburg, PA.

VTRS At a Glance

Viatris, Inc.
Robert J. Coury Global Center
Canonsburg, Pennsylvania 15317
Phone 1-724-514-1800 Revenue 14.71B
Industry Pharmaceuticals: Major Net Income -634,200,000.00
Sector Health Technology Employees 32,000
Fiscal Year-end 12 / 2025
View SEC Filings

VTRS Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio 1.01
Price to Book Ratio 0.797
Price to Cash Flow Ratio 6.451
Enterprise Value to EBITDA 6.202
Enterprise Value to Sales 1.927
Total Debt to Enterprise Value 0.505

VTRS Efficiency

Revenue/Employee 459,678.125
Income Per Employee -19,818.75
Receivables Turnover 4.177
Total Asset Turnover 0.33

VTRS Liquidity

Current Ratio 1.556
Quick Ratio 0.889
Cash Ratio 0.144

VTRS Profitability

Gross Margin 42.316
Operating Margin 12.65
Pretax Margin -4.237
Net Margin -4.311
Return on Assets -1.422
Return on Equity -3.244
Return on Total Capital -1.925
Return on Invested Capital -1.82

VTRS Capital Structure

Total Debt to Total Equity 76.808
Total Debt to Total Capital 43.442
Total Debt to Total Assets 34.49
Long-Term Debt to Equity 76.296
Long-Term Debt to Total Capital 43.152
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Viatris Inc. - VTRS

Collapse All in section
All values USD millions. 2021 2022 2023 2024 5-year trend
Sales/Revenue
17.86B 16.17B 15.38B 14.71B
Sales Growth
+49.53% -9.42% -4.90% -4.37%
Cost of Goods Sold (COGS) incl D&A
11.66B 9.49B 8.81B 8.49B
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
3.21B 2.85B 2.68B 2.71B
Depreciation
509.50M 349.50M 362.10M 357.00M
Amortization of Intangibles
2.70B 2.50B 2.32B 2.35B
COGS Growth
+55.39% -18.65% -7.08% -3.73%
Gross Income
6.20B 6.69B 6.57B 6.22B
Gross Income Growth
+39.62% +7.94% -1.80% -5.23%
Gross Profit Margin
+34.70% +41.35% +42.70% +42.32%
2021 2022 2023 2024 5-year trend
SG&A Expense
4.53B 4.18B 4.51B 4.36B
Research & Development
737.80M 660.80M 793.00M 802.90M
Other SG&A
3.79B 3.52B 3.72B 3.56B
SGA Growth
+47.90% -7.72% +8.03% -3.34%
Other Operating Expense
- - - -
-
Unusual Expense
1.69B 1.07B 1.28B 1.59B
EBIT after Unusual Expense
(25.60M) 1.44B 777.20M 269.10M
Non Operating Income/Expense
(6.90M) 1.96B 600.00K (337.60M)
Non-Operating Interest Income
- - - -
-
Equity in Earnings of Affiliates
- - - (61.90M)
-
Interest Expense
631.90M 587.90M 574.90M 554.70M
Interest Expense Growth
+28.10% -6.96% -2.21% -3.51%
Gross Interest Expense
631.90M 587.90M 574.90M 554.70M
Interest Capitalized
- - - -
-
Pretax Income
(664.40M) 2.81B 202.90M (623.20M)
Pretax Income Growth
+7.88% +523.42% -92.79% -407.15%
Pretax Margin
-3.72% +17.39% +1.32% -4.24%
Income Tax
604.70M 734.60M 148.20M 11.00M
Income Tax - Current - Domestic
20.30M 141.80M 4.50M 120.20M
Income Tax - Current - Foreign
(91.30M) 618.70M 530.80M 658.40M
Income Tax - Deferred - Domestic
(193.50M) 284.00M 296.00M (120.40M)
Income Tax - Deferred - Foreign
869.20M (309.90M) (683.10M) (647.20M)
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - (61.90M)
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
(1.27B) 2.08B 54.70M (634.20M)
Minority Interest Expense
- - - -
-
Net Income
(1.27B) 2.08B 54.70M (634.20M)
Net Income Growth
-89.45% +263.79% -97.37% -1,259.41%
Net Margin Growth
-7.11% +12.85% +0.36% -4.31%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
(1.27B) 2.08B 54.70M (634.20M)
Preferred Dividends
- - - -
-
Net Income Available to Common
(1.27B) 2.08B 54.70M (634.20M)
EPS (Basic)
-1.0499 1.7149 0.0456 -0.5315
EPS (Basic) Growth
+5.78% +263.34% -97.34% -1,265.57%
Basic Shares Outstanding
1.21B 1.21B 1.20B 1.19B
EPS (Diluted)
-1.0499 1.7074 0.0453 -0.5315
EPS (Diluted) Growth
+5.78% +262.63% -97.35% -1,273.29%
Diluted Shares Outstanding
1.21B 1.22B 1.21B 1.19B
EBITDA
4.88B 5.36B 4.73B 4.57B
EBITDA Growth
+36.48% +9.92% -11.76% -3.44%
EBITDA Margin
+27.33% +33.16% +30.77% +31.06%

Snapshot

Average Recommendation OVERWEIGHT Average Target Price 11.20
Number of Ratings 11 Current Quarters Estimate 0.557
FY Report Date 06 / 2025 Current Year's Estimate 2.224
Last Quarter’s Earnings 0.50 Median PE on CY Estimate N/A
Year Ago Earnings 2.65 Next Fiscal Year Estimate 2.44
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 4 4 6 6
Mean Estimate 0.56 0.61 2.22 2.44
High Estimates 0.59 0.66 2.31 2.52
Low Estimate 0.53 0.58 2.15 2.37
Coefficient of Variance 5.24 6.36 2.52 2.47

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 3 3 2
OVERWEIGHT 1 1 1
HOLD 6 6 6
UNDERWEIGHT 1 1 1
SELL 0 0 1
MEAN Overweight Overweight Hold

Insider Actions for Viatris Inc. - VTRS

Date Name Shares Transaction Value
Mar 11, 2025 Harry A. Korman Director 23,660 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 11, 2025 James Marshall Kilts Director 23,660 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 11, 2025 Leo Groothuis Director 23,660 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 11, 2025 Rogério Vivaldi Coelho Director 23,660 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 11, 2025 Theodora Mistras Chief Financial Officer 125,132 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 11, 2025 Wyllie Don Cornwell Director 23,660 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 11, 2025 JoEllen Lyons Dillon Director 23,660 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 11, 2025 Melina E. Higgins Director 23,660 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 11, 2025 Scott Andrew Smith Chief Executive Officer; Director 373,555 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 11, 2025 Corinne Le Goff Chief Commercial Officer 132,493 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 11, 2025 Richard A. Mark Director 23,660 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 11, 2025 Paul B. Campbell See Remarks 82,808 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 11, 2025 Mark W. Parrish Director 23,660 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 11, 2025 Rajiv Malik Director 23,660 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 11, 2025 Brian S. Roman Chief Legal Officer 93,849 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 11, 2025 Elisha Wade Finney Director 23,660 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 6, 2025 Harry A. Korman Director N/A Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Mar 6, 2025 Harry A. Korman Director N/A Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Mar 6, 2025 Theodora Mistras Chief Financial Officer 2,645 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Mar 6, 2025 Melina E. Higgins Director N/A Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00

Viatris Inc. in the News